Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma
NCT02739555 · Assistance Publique - Hôpitaux de Paris · PHASE3 · terminated · last registry update 2022-02-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has been conducted until the end of the research; participants are no longer receiving an intervention or being examined; but recruitment isn't completed (15 % enrolled in the stud)” | – | Registry record, Assistance Publique - Hôpitaux de Paris |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-05Results posted on the registry: Hartmut Malluche, MD, Alendronate + Teriparatide (NCT02440581)
- 2022-12-06Phase 3 first posted: Shenzhen People's Hospital, Denosumab 60 mg/ml [Prolia] + Zoledronate (NCT05638399)
- 2022-11-02Phase 3 first posted: Xeolas Pharmaceuticals Limited, Soludronate® + sterile saline (NCT05602493)
- 2022-10-12Results posted on the registry: Massachusetts General Hospital, Denosumab 60 MG [Prolia] + Placebo Injection (NCT03292146)
- 2022-07-19Also stopped (withdrawn): University Hospitals Cleveland Medical Center, Risedronate (NCT00594334)
- 2022-05-27Also stopped (terminated): University of Leeds, zoledronic acid (NCT00458796)
- 2022-05-26Also stopped (terminated): University College Dublin, Alendronate + Placebo (NCT02322099)
- 2022-03-31Phase 3 first posted: Shandong New Time Pharmaceutical Co., LTD, Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo (NCT05305183)
- 2022-03-02Results posted on the registry: Ultragenyx Pharmaceutical Inc, setrusumab + zoledronic acid (optional) (NCT03118570)
- 2022-02-25Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib + Zoledronic Acid (NCT00566618)
- 2021-12-21Phase 3 first posted: Assiut University, Zoledronic Acid 4 MG (NCT05164952)
- 2021-11-08Also stopped (terminated): Institut Bergonié, Glivec (NCT00210119)
- 2021-11-03Phase 3 first posted: Shenzhen People's Hospital, Denosumab + Zoledronic acid (NCT05106517)
- 2021-10-28Results posted on the registry: Institut Bergonié, Glivec (NCT00210119)
- 2021-10-22Also stopped (terminated): Centre Leon Berard, denosumab (NCT03408652)
- 2021-10-18Results posted on the registry: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 99Tc-MDP + Fosamax (NCT02304757)
- 2021-09-29Results posted on the registry: Mahidol University, Generic alendronate (NCT02371252)
- 2021-06-25Also stopped (terminated): University of Aarhus, Zoledronic acid + Teriparatide (NCT01679080)
- 2021-06-22Also stopped (terminated): First Affiliated Hospital, Sun Yat-Sen University, Zoledronate (NCT01623908)
- 2021-06-10Phase 3 first posted: Wake Forest University Health Sciences, Risedronate + Placebo (NCT04922333)
- 2021-06-02Results posted on the registry: Northwestern University, Zoledronic acid + Placebo (NCT02325414)
- 2021-05-26Results posted on the registry: Novartis Pharmaceuticals, zoledronic acid (NCT00622505)
- 2021-05-26Results posted on the registry: Novartis Pharmaceuticals, Zoledronic Acid (NCT00740129)
- 2021-04-29Results posted on the registry: Massachusetts General Hospital, Zoledronic Acid (NCT03424239)
- 2021-04-14Results posted on the registry: Karolinska Institutet, Risedronate (NCT01950169)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision